Cargando…

Curative Treatment of Candidiasis by the Live Biotherapeutic Microorganism Lactobacillus rhamnosus Lcr35(®) in the Invertebrate Model Caenorhabditis elegans: First Mechanistic Insights

The resistance of Candida albicans to conventional drug treatments, as well as the recurrence phenomena due to dysbiosis caused by antifungal treatments, have highlighted the need to implement new therapeutic methodologies. The antifungal potential of live biotherapeutic products (LBP) has already b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poupet, Cyril, Veisseire, Philippe, Bonnet, Muriel, Camarès, Olivier, Gachinat, Marylise, Dausset, Caroline, Chassard, Christophe, Nivoliez, Adrien, Bornes, Stéphanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022838/ https://www.ncbi.nlm.nih.gov/pubmed/31878039 http://dx.doi.org/10.3390/microorganisms8010034

Ejemplares similares

Lactobacillus rhamnosus Lcr35 as an effective treatment for preventing Candida albicans infection in the invertebrate model Caenorhabditis elegans: First mechanistic insights
por: Poupet, Cyril, et al.
Publicado: (2019)

In vivo investigation of Lcr35(®) anti-candidiasis properties in Caenorhabditis elegans reveals the involvement of highly conserved immune pathways
por: Poupet, Cyril, et al.
Publicado: (2022)

Investigation into In Vitro and In Vivo Caenorhabditis elegans Models to Select Cheese Yeasts as Probiotic Candidates for their Preventive Effects against Salmonella Typhimurium
por: Veisseire, Philippe, et al.
Publicado: (2020)

Identification of sulfur components enhancing the anti-Candida effect of Lactobacillus rhamnosus Lcr35
por: Dausset, Caroline, et al.
Publicado: (2020)

Caenorhabditis elegans, a Host to Investigate the Probiotic Properties of Beneficial Microorganisms
por: Poupet, Cyril, et al.
Publicado: (2020)

Mechanistic Approach to Stability Studies as a Tool for the Optimization and Development of New Products Based on L. rhamnosus Lcr35® in Compliance with Current Regulations
por: Muller, Claudia, et al.
Publicado: (2013)

Comparative phase I randomized open-label pilot clinical trial of Gynophilus(®) (Lcr regenerans(®)) immediate release capsules versus slow release muco-adhesive tablets
por: Dausset, Caroline, et al.
Publicado: (2018)

Characterization of Nitrite Degradation by Lactobacillus casei subsp. rhamnosus LCR 6013
por: Liu, Dong-mei, et al.
Publicado: (2014)

Dose-Dependent Immunomodulation of Human Dendritic Cells by the Probiotic Lactobacillus rhamnosus Lcr35
por: Evrard, Bertrand, et al.
Publicado: (2011)

Development of an innovative methodology combining chemical fractionation and in vivo analysis to investigate the biological properties of cheese
por: Cardin, Guillaume, et al.
Publicado: (2020)

A Mechanistic Study of the Antiaging Effect of Raw-Milk Cheese Extracts
por: Cardin, Guillaume, et al.
Publicado: (2021)

Potentials and limitations of microorganisms as renal failure biotherapeutics
por: Jain, Poonam, et al.
Publicado: (2009)

LcrQ Coordinates with the YopD-LcrH Complex To Repress lcrF Expression and Control Type III Secretion by Yersinia pseudotuberculosis
por: Fei, Keke, et al.
Publicado: (2021)

Effect of vaginal probiotics containing Lactobacillus casei rhamnosus (Lcr regenerans) on vaginal dysbiotic microbiota and pregnancy outcome, prospective, randomized study
por: Petricevic, Ljubomir, et al.
Publicado: (2023)

External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV
por: Poynard, Thierry, et al.
Publicado: (2021)

In Vivo Efficacy of Lacticaseibacillus rhamnosus L8020 in a Mouse Model of Oral Candidiasis
por: Ito, Rei, et al.
Publicado: (2021)

Interaction of the Yersinia pestis type III regulatory proteins LcrG and LcrV occurs at a hydrophobic interface
por: Matson, Jyl S, et al.
Publicado: (2002)

LcrQ Blocks the Role of LcrF in Regulating the Ysc-Yop Type III Secretion Genes in Yersinia pseudotuberculosis
por: Li, Lamei, et al.
Publicado: (2014)

Interaction of the Yersinia pestis type III regulatory proteins LcrG and LcrV occurs at a hydrophobic interface: correction
por: Matson, Jyl S, et al.
Publicado: (2002)

LCR1 and LCR2, two multi‐analyte blood tests to assess liver cancer risk in patients without or with cirrhosis
por: Poynard, Thierry, et al.
Publicado: (2018)

Toxicity of Per- and Polyfluoroalkyl Substances to Aquatic Invertebrates, Planktons, and Microorganisms
por: Ma, Tingting, et al.
Publicado: (2022)

Dialogue between Staphylococcus aureus SA15 and Lactococcus garvieae strains experiencing oxidative stress
por: Queiroux, Clothilde, et al.
Publicado: (2018)

Advances in the Development of Biotherapeutics
por: Oliveira, Pedro H., et al.
Publicado: (2015)

Integrated BioTherapeutics
por: Aman, M. Javad
Publicado: (2018)

Promising Antiparasitic Natural and Synthetic Products from Marine Invertebrates and Microorganisms
por: Zhang, Mingyue, et al.
Publicado: (2023)

Numerical Processing Impairment in 22q11.2 (LCR22-4 to LCR22-5) Microdeletion: A Cognitive-Neuropsychological Case Study
por: Oliveira, Lívia de Fátima Silva, et al.
Publicado: (2018)

One Step Closer to the Understanding of the Relationship IDR-LCR-Structure
por: Gonçalves-Kulik, Mariane, et al.
Publicado: (2023)

Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics
por: Martin, Kyle P., et al.
Publicado: (2023)

Polymorphism in the Yersinia LcrV Antigen Enables Immune Escape From the Protection Conferred by an LcrV-Secreting Lactococcus Lactis in a Pseudotuberculosis Mouse Model
por: Daniel, Catherine, et al.
Publicado: (2019)

Millimeter-Sized Marine Plastics: A New Pelagic Habitat for Microorganisms and Invertebrates
por: Reisser, Julia, et al.
Publicado: (2014)

In vivo selection of novel biotherapeutics
por: Ruozi, Giulia, et al.
Publicado: (2015)

Posttranslational Modifications and the Immunogenicity of Biotherapeutics
por: Jefferis, Roy
Publicado: (2016)

The Development Pathway for Biosimilar Biotherapeutics
por: Zarbin, Marco
Publicado: (2020)

The Emerging Biotherapeutic Agent: Akkermansia
por: Kalia, Vipin Chandra, et al.
Publicado: (2021)

Editorial: Characterization of biotherapeutic products
por: Rathore, Anurag S., et al.
Publicado: (2022)

Live Biotherapeutic Products, A Road Map for Safety Assessment
por: Rouanet, Alice, et al.
Publicado: (2020)

LcrG secretion is not required for blocking of Yops secretion in Yersinia pestis
por: Reina, Laura D, et al.
Publicado: (2008)

Glutathionylation of Yersinia pestis LcrV and Its Effects on Plague Pathogenesis
por: Mitchell, Anthony, et al.
Publicado: (2017)

Study on Propagation Depth of Ultrasonic Longitudinal Critically Refracted (LCR) Wave
por: Liu, Yongmeng, et al.
Publicado: (2020)

Pilot Study on the Use of DNA Priming Immunization to Enhance Y. pestis LcrV-Specific B Cell Responses Elicited by a Recombinant LcrV Protein Vaccine
por: Li, Wei, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ht3qovnci43m24tpdrr966tltn